Discovery of oxazole and triazole derivatives as potent and selective S1P1 agonists through pharmacophore-guided design

Discovery of oxazole and triazole derivatives as potent and selective S1P1 agonists through pharmacophore-guided design Discovery of Potent 3,5-Diphenyl-1,2,4-oxadiazole Sphingosine-1-phosphate-1 (S1P₁) Receptor Agonists with Exceptional Selectivity against S1P₂ and S1P₃ Discovery of Novel Sphingosine-1-Phosphate-1 Receptor Agonists for the Treatment of Multiple Sclerosis Discovery of Novel 1,2,4-Thiadiazole Derivatives as Potent, Orally Active Agonists of Sphingosine 1-Phosphate Receptor Subtype 1 (S1P₁) Removal of Sphingosine 1-Phosphate Receptor-3 (S1P₃) Agonism is Essential, But Inadequate to Obtain Immunomodulating 2-Aminopropane-1,3-diol S1P₁ Agonists with Reduced Effect on Heart Rate Novel S1P₁ Receptor Agonists – Part 1: From Pyrazoles to Thiophenes Discovery of 3-arylpropionic acids as potent agonists of sphingosine-1-phosphate receptor-1 (S1P1) with high selectivity against all other known S1P receptor subtypes A Rational Utilization of High-Throughput Screening Affords Selective, Orally Bioavailable 1-Benzyl-3-carboxyazetidine Sphingosine-1-phosphate-1 Receptor Agonists 2-Imino-thiazolidin-4-one Derivatives as Potent, Orally Active S1P₁Receptor Agonists Discovery and Structure–Activity Relationship (SAR) of a Series of Ethanolamine-Based Direct-Acting Agonists of Sphingosine-1-phosphate (S1P₁)